2022 annual financial data
Sutro Biopharma 2022 Operating cash flow growth
Direct answer
Operating cash flow growth was 104.35%.
Operating income was -128,943,000 USD and net income was -119,204,000 USD.
Operating cash flow was 3,549,000 USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 67,772,000 USD
- Operating income
- -128,943,000 USD
- Net income
- -119,204,000 USD
- Operating cash flow
- 3,549,000 USD